Clinical Trial Update: Phase II Iressa & Carbo/Gem in NSCLC [Phase 2]

View source ↗

Summary

Phase II study evaluating Iressa (gefitinib) in combination with carboplatin and gemcitabine for non-small-cell lung cancer has completed and results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Gemcitabine (Gemcitabine)
• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2009-08-03